23andMe Holding Acquired by TTAM Research Institute

23andMe Holding ( (MEHCQ) ) just unveiled an announcement.

On March 23, 2025, 23andMe Holding Co. filed for Chapter 11 bankruptcy and conducted an auction to sell its assets. Initially, Regeneron Pharmaceuticals was selected as the successful bidder with a $256 million offer, but TTAM Research Institute, led by 23andMe’s co-founder Anne Wojcicki, later won the bid with a $305 million offer. The transaction, subject to court approval, includes commitments from TTAM to uphold 23andMe’s privacy policies and enhance consumer data protections. The sale aims to maximize value for stakeholders and continue 23andMe’s mission under TTAM’s leadership.

The most recent analyst rating on (MEHCQ) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on 23andMe Holding stock, see the MEHCQ Stock Forecast page.

Spark’s Take on MEHCQ Stock

According to Spark, TipRanks’ AI Analyst, MEHCQ is a Neutral.

23andMe Holding’s overall stock performance is weak, primarily due to significant financial challenges, including declining revenues and persistent net losses. The technical analysis also suggests a bearish trend with no strong momentum to reverse it. The negative valuation metrics further highlight the company’s struggles with profitability. Improvements in financial performance and strategic adjustments to reverse negative trends are critical for enhancing investor confidence.

To see Spark’s full report on MEHCQ stock, click here.

More about 23andMe Holding

23andMe Holding Co. is a genetics-led consumer healthcare and biotechnology company focused on empowering a healthier future through its Personal Genome Service and Research Services business lines, as well as its telehealth services operated by Lemonaid Health, Inc.

Average Trading Volume: 4,056,303

Technical Sentiment Signal: Hold

Current Market Cap: $151.5M

For an in-depth examination of MEHCQ stock, go to TipRanks’ Overview page.